The history of attempts — and why this disclosure is unusual

Charles Barkley played eleven All-Star seasons across the Philadelphia 76ers, the Phoenix Suns, and the Houston Rockets between 1984 and 2000. He was an MVP, a Dream Teamer, a Hall of Famer in 2006. He has been the loudest, funniest, most quotable voice on TNT's Inside the NBA since 2000 — 25 years and counting. He has been publicly weight-discussed for nearly all of those 25 years.

The reason Barkley's recent disclosure matters: he has been open, repeatedly, about previous weight-loss attempts that did not work. Weight Watchers. Personal trainers. Various diet protocols. He has lost weight before and gained it back. He has been candid that, by his sixties, he was tired of the cycle. He had cardiovascular and joint concerns. He has talked publicly about his daughter Christiana and his grandchildren as practical drivers of the current attempt.

What changed in 2024 was that he disclosed the tool. He said, on TNT and in print, that he was on Mounjaro. He explained why he chose it, what it had done for his appetite, and what his prescriber was watching. That is rare. Most celebrities deny. Some confirm and pitch. Barkley confirmed and reported.

"I'm 6'6", I'm in my 60s, I have grandkids. I want to be around. I'm on Mounjaro. My doctor put me on it. I'm not hiding it from anybody." — Charles Barkley, paraphrased from Inside the NBA, 2024.

The Mounjaro disclosure — what it actually is

Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication produced by Eli Lilly. It is structurally a dual agonist — it activates both the GLP-1 receptor (the same target as semaglutide / Ozempic / Wegovy) and the GIP receptor (a related incretin hormone). Mounjaro is FDA-approved for type 2 diabetes. Zepbound, which is the same molecule, is FDA-approved for chronic weight management in qualifying adults.

The clinical evidence for tirzepatide is the strongest of any current weight-management medication. The SURMOUNT-1 trial published in NEJM in 2022 — 2,539 adults with obesity randomized for 72 weeks — found weight loss of approximately 15% at the 5 mg dose, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% with placebo. That is the highest mean weight loss ever produced by a pharmacological intervention short of bariatric surgery. For comparison, our semaglutide vs tirzepatide comparison walks through both molecules side by side.

Barkley's 60+ pound loss is consistent with what tirzepatide produces in his weight class. A man starting in the 350-pound range losing 60 pounds is roughly 17% body-weight reduction — straight down the SURMOUNT-1 average. The medication does what the trials say it does.

The walking habit — the underrated piece

Barkley has been clear that the medication is not the whole story. He walks daily. He has talked about walking his neighborhood, walking before TNT shoots, walking with his wife Maureen. He has not described going to a gym, lifting weights, or training cardiovascularly in a structured way — but the walking floor is real.

For a 6'6" man in his early 60s with documented joint history, walking is the right floor. The CDC adult activity guidelines ask for 150 minutes per week of moderate activity. A 2023 Circulation analysis of 226,889 adults found mortality benefit beginning at about 2,500 daily steps and continuing to improve up to about 8,800. Walking is the activity floor that compounds with GLP-1 medication. It preserves muscle, it preserves bone density, and it gives the loss structural durability.

The piece worth flagging for any reader considering a GLP-1: medication without movement produces weight loss but does not produce body recomposition. Muscle and bone are lost alongside fat in pharmacological-only protocols. Walking — and ideally some resistance work — is the floor that protects lean mass during the deficit. Read our walking-for-weight-loss method page for the full version.

The medical caveat — what to actually do with this story

Charles Barkley is on a medication prescribed by a licensed doctor, monitored over time, in a body and life that has specific medical context. None of those things transfer directly to a reader. The most useful thing this article can do for someone considering a GLP-1 is point them at the right resources and tell them, plainly, what to ask.

The right resources, ranked by usefulness:

• A licensed prescriber. Your primary care doctor or an endocrinologist is the only person who can tell you if a GLP-1 medication is appropriate for your body.
• The Real Easy Diet GLP-1 explainer — what semaglutide and tirzepatide are, what they do, what they cost, what the trial evidence shows.
• The semaglutide vs tirzepatide comparison — Mounjaro vs Wegovy / Ozempic, head to head.
• The side-effects guide — what to expect and what to flag.
• The off-ramp guide — how to plan an exit without regain.

What to ask your prescriber: Am I a candidate? What is the starting dose and titration plan? What side effects are you watching for? How will we measure success? What is the stopping plan? What does long-term maintenance look like? If you cannot get clear answers, find a different prescriber.

An honest read

Charles Barkley's story is useful because it is honest. He tried the old way for years. It did not work for him. He tried the new way — with medical supervision — and it has worked. He has been transparent about the tool. He has been clear about the daily walking floor. He has been candid about staying on the medication for the foreseeable future and the regain risk if he stops.

The honest read for non-celebrities: GLP-1 medications are real tools. They are not magic, not failure, and not for everyone. For some adults — particularly those with significant excess weight, cardiovascular risk, or type 2 diabetes — they may be the right tool. For others, they will not be. The decision is between a person and their prescriber. A celebrity disclosure is useful as evidence that real adults are using these medications openly. It is not a substitute for a real medical conversation.

What you should not do: take "Charles Barkley lost 60 pounds on Mounjaro" as a reason to source the medication from an unregulated online pharmacy or a compounding shop with no oversight. The FDA has documented serious safety problems with unregulated compounded GLP-1s. If you and your prescriber decide the medication is right, get it through a real prescriber and a real pharmacy.

Real Easy Diet does not prescribe medication and does not give medical advice. Talk to a licensed prescriber before considering Mounjaro, Zepbound, Ozempic, Wegovy, or any GLP-1 medication.

FAQ

Read more on Real Easy Diet

• Ozempic for weight loss — the full GLP-1 explainer
• Semaglutide vs tirzepatide — head-to-head
• Tirzepatide vs retatrutide — what's coming next
• GLP-1 side-effects management guide
• The GLP-1 off-ramp — preventing rebound
• Lily Allen on Ozempic — what she said
• Andy Reid on plant-forward + walking (no GLP-1)
• Walking for weight loss — the full method

Sources

• NBA.com / TNT — Inside the NBA Coverage Index
• The Athletic — Charles Barkley on Mounjaro
• NEJM — SURMOUNT-1 Tirzepatide for Obesity
• FDA — GLP-1 Safety Information
• Circulation — Steps and Mortality, 226,889 Adults
• CDC — Adult Physical Activity Guidelines
• Wikipedia — Charles Barkley

Informational only. Consult a licensed healthcare provider before considering Mounjaro, Zepbound, Ozempic, Wegovy, or any GLP-1 medication. This article reports public statements; it is not a recommendation.